+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine



Two cases of HER2-positive advanced or metastatic breast cancer, responding to lapatinib and capecitabine



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 37(11): 2165-2168



The first patient was a 59-year-old woman who was diagnosed with invasive scirrhous carcinoma. The tumor was estrogen receptor (ER)-positive, progesterone receptor (PgR)-positive, and human epidermal growth factor receptor 2 (HER2)-positive. The patient was treated with adjuvant chemotherapy and endocrine therapy after surgery. Liver metastases developed 5 years after surgery. She was treated with trastuzumab combined with vinorelbine, paclitaxel, or docetaxel. The liver metastases increased in size, 9 years after surgery, and she was treated with lapatinib and capecitabine. The efficacy of chemotherapy was judged as a partial response. The second patient was a 74-year-old woman who was diagnosed with invasive ductal carcinoma in 2005. The tumor was ER-negative, PgR-positive, and HER2-positive; she was treated with trastuzumab and paclitaxel. She developed dyspnea in January 2010. Chest radiograph showed increased lung metastases and left pleural effusion; she was treated with lapatinib and capecitabine. Lung metastases decreased and left pleural effusion disappeared after the first cycle of chemotherapy. The efficacy of chemotherapy was judged as a partial response.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 056715468

Download citation: RISBibTeXText

PMID: 21084819


Related references

Clinical recommendations for the use of lapatinib ditosylate plus capecitabine for patients with advanced or metastatic HER2-positive breast cancer. Asia-Pacific Journal of Clinical Oncology 5(1): 4-16, 2009

Trastuzumab-Emtansin vs. Capecitabin plus Lapatinib bei Patienten mit vorbehandeltem HER2-positivem metastasierten Mammakarzinom; Trastuzumab emtansine vs. capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer;. Der Onkologe 23(11): 940-942, 2017

Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab. Oncology 93(1): 51-61, 2017

Correlation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancer. Plos one 7(7): E39943, 2012

Lapatinib plus capecitabine for HER2-positive advanced breast cancer. New England Journal of Medicine 355(26): 2733-2743, 2006

Lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer. Clinical Advances in Hematology and Oncology 5(6): 456-458, 2007

Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. Journal of Clinical Oncology 26(15_Suppl): 1016-1016, 2016

Lapatinib in combination with capecitabine in the management of ErbB2-positive (HER2-positive) advanced breast cancer. Biologics 2(1): 61-65, 2008

Lapatinib plus capecitabine for HER2-positive advanced breast cancer (vol 355, pg 2733, 2006). New England Journal of Medicine 356(14): 1487, 2007

Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
. International Journal of Clinical Pharmacology and Therapeutics 56(2): 72-80, 2018

Efficacy and toxicity of lapatinib plus capecitabine therapy in HER2-positive metastatic breast cancer. Gan to Kagaku Ryoho. Cancer and ChemoTherapy 39(11): 1675-1679, 2012

Safety Profile and Costs of Related Adverse Events of Trastuzumab Emtansine for the Treatment of HER2-Positive Locally Advanced or Metastatic Breast Cancer Compared to Capecitabine Plus Lapatinib from the Perspective of the Canadian Health-Care System. Clinical Drug Investigation 35(8): 487-493, 2015

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast 40: 67-75, 2018

A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP. Breast 40: 67-75, 2018

Correlation of efficacy between rash and lapatinib/capecitabine therapy in Japanese HER2-positive metastatic breast cancer patients. Journal of Clinical Oncology 29(27_Suppl): 62-62, 2016